Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00454181 | Treatment of Oral Warts in HIV+ Patients | PHASE2 | COMPLETED | 59 | — | — | Feb 1, 2007 | Oct 1, 2009 | Sep 16, 2011 | 12 | United States |
Number of subjects with a 75% or greater decrease from baseline to week 24 in total oral wart area
| Arm | Type | Description |
|---|---|---|
| IFN lozenges | EXPERIMENTAL | 500 IU Interferon-alpha lozenges for oral dissolution |
| placebo lozenges | PLACEBO_COMPARATOR | 200 mg lozenges containing anhydrous crystalline maltose |
| Name | Type | Description |
|---|---|---|
| Interferon-alpha | DRUG | 500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks |
| placebo | OTHER | 200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks |
Inclusion Criteria: * Must have tested positive for HIV. * Must have two or more warts inside the mouth. * Must be receiving a standard course of anti-retroviral therapy (HAART). Exclusion Criteria: * Must not be receiving oral or injected steroids. * Must not be taking other drugs for treatment ...